Details
| Original language | English |
|---|---|
| Article number | 101299 |
| Journal | The journal of nutrition |
| Volume | 156 |
| Issue number | 2 |
| Early online date | 27 Dec 2025 |
| Publication status | Published - Feb 2026 |
Abstract
BACKGROUND: Adequate levels of long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are critical for maternal health and fetal development during pregnancy. Despite their importance, global data on maternal EPA+DHA blood levels remain sparse and inconsistent, partially due to differences in measurement methodologies.
OBJECTIVE: To assess global maternal EPA+DHA blood levels during pregnancy by synthesizing data from observational studies and randomized controlled trials from the last 20 years (2004 to 2025).
METHODS: Non-RBC-based EPA+DHA blood levels from published studies were standardized using conversion equations to estimate relative EPA+DHA percentages in red blood cells (estimated omega-3 index = eO3I). Country mean eO3I levels were classified into four categories based on literature-defined thresholds.
RESULTS: An analysis of 66 studies involving 33,390 pregnant women from 28 countries revealed significant geographical disparities in eO3I levels. Only the Seychelles, Norway and Ghana achieved desirable levels (>8%). Some Asian countries (Japan, Taiwan, Singapore), Malawi, Tanzania, and Northern European nations (Belgium, Netherlands, Iceland, Denmark, Sweden) exhibited sufficient/moderate levels (>6 to 8%). Most countries, including the USA, Canada, Mexico, Brazil Chile, Australia, the United Kingdom, Germany, Switzerland, Italy, Croatia, and Spain, demonstrated insufficient/low levels (>4 to 6%). Meanwhile, China, India, and Iran showed very low/undesirable levels (≤4%).
CONCLUSIONS: These findings highlight widespread insufficiency in maternal EPA+DHA status globally, with particularly severe deficiencies observed in Asia and parts of Europe. This study underscores the need for more research to ultimately define the optimal EPA+DHA levels during pregnancy using standardized blood biomarkers, along with pregnancy-specific reference ranges, to facilitate targeted nutritional strategies aimed at optimizing health outcomes for both mother and child. Future studies should focus on addressing data gaps, refining intake recommendations, and promoting accessible supplementation strategies.
Keywords
- erythrocyte fatty acid, maternal health, omega-3 fatty acids (EPA/DHA), Omega-3 Index, pregnancy nutrition
ASJC Scopus subject areas
- Medicine(all)
- Medicine (miscellaneous)
- Nursing(all)
- Nutrition and Dietetics
Sustainable Development Goals
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: The journal of nutrition, Vol. 156, No. 2, 101299, 02.2026.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - Global Comparison of Erythrocyte EPA and DHA Levels in Pregnant Women
AU - Deutsch, Tessa
AU - Harris, William S
AU - Jackson, Kristina Harris
AU - Hahn, Andreas
AU - Schuchardt, Jan Philipp
N1 - Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
PY - 2026/2
Y1 - 2026/2
N2 - BACKGROUND: Adequate levels of long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are critical for maternal health and fetal development during pregnancy. Despite their importance, global data on maternal EPA+DHA blood levels remain sparse and inconsistent, partially due to differences in measurement methodologies.OBJECTIVE: To assess global maternal EPA+DHA blood levels during pregnancy by synthesizing data from observational studies and randomized controlled trials from the last 20 years (2004 to 2025).METHODS: Non-RBC-based EPA+DHA blood levels from published studies were standardized using conversion equations to estimate relative EPA+DHA percentages in red blood cells (estimated omega-3 index = eO3I). Country mean eO3I levels were classified into four categories based on literature-defined thresholds.RESULTS: An analysis of 66 studies involving 33,390 pregnant women from 28 countries revealed significant geographical disparities in eO3I levels. Only the Seychelles, Norway and Ghana achieved desirable levels (>8%). Some Asian countries (Japan, Taiwan, Singapore), Malawi, Tanzania, and Northern European nations (Belgium, Netherlands, Iceland, Denmark, Sweden) exhibited sufficient/moderate levels (>6 to 8%). Most countries, including the USA, Canada, Mexico, Brazil Chile, Australia, the United Kingdom, Germany, Switzerland, Italy, Croatia, and Spain, demonstrated insufficient/low levels (>4 to 6%). Meanwhile, China, India, and Iran showed very low/undesirable levels (≤4%).CONCLUSIONS: These findings highlight widespread insufficiency in maternal EPA+DHA status globally, with particularly severe deficiencies observed in Asia and parts of Europe. This study underscores the need for more research to ultimately define the optimal EPA+DHA levels during pregnancy using standardized blood biomarkers, along with pregnancy-specific reference ranges, to facilitate targeted nutritional strategies aimed at optimizing health outcomes for both mother and child. Future studies should focus on addressing data gaps, refining intake recommendations, and promoting accessible supplementation strategies.
AB - BACKGROUND: Adequate levels of long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs), specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are critical for maternal health and fetal development during pregnancy. Despite their importance, global data on maternal EPA+DHA blood levels remain sparse and inconsistent, partially due to differences in measurement methodologies.OBJECTIVE: To assess global maternal EPA+DHA blood levels during pregnancy by synthesizing data from observational studies and randomized controlled trials from the last 20 years (2004 to 2025).METHODS: Non-RBC-based EPA+DHA blood levels from published studies were standardized using conversion equations to estimate relative EPA+DHA percentages in red blood cells (estimated omega-3 index = eO3I). Country mean eO3I levels were classified into four categories based on literature-defined thresholds.RESULTS: An analysis of 66 studies involving 33,390 pregnant women from 28 countries revealed significant geographical disparities in eO3I levels. Only the Seychelles, Norway and Ghana achieved desirable levels (>8%). Some Asian countries (Japan, Taiwan, Singapore), Malawi, Tanzania, and Northern European nations (Belgium, Netherlands, Iceland, Denmark, Sweden) exhibited sufficient/moderate levels (>6 to 8%). Most countries, including the USA, Canada, Mexico, Brazil Chile, Australia, the United Kingdom, Germany, Switzerland, Italy, Croatia, and Spain, demonstrated insufficient/low levels (>4 to 6%). Meanwhile, China, India, and Iran showed very low/undesirable levels (≤4%).CONCLUSIONS: These findings highlight widespread insufficiency in maternal EPA+DHA status globally, with particularly severe deficiencies observed in Asia and parts of Europe. This study underscores the need for more research to ultimately define the optimal EPA+DHA levels during pregnancy using standardized blood biomarkers, along with pregnancy-specific reference ranges, to facilitate targeted nutritional strategies aimed at optimizing health outcomes for both mother and child. Future studies should focus on addressing data gaps, refining intake recommendations, and promoting accessible supplementation strategies.
KW - erythrocyte fatty acid
KW - maternal health
KW - omega-3 fatty acids (EPA/DHA)
KW - Omega-3 Index
KW - pregnancy nutrition
UR - http://www.scopus.com/inward/record.url?scp=105027873464&partnerID=8YFLogxK
U2 - 10.1016/j.tjnut.2025.101299
DO - 10.1016/j.tjnut.2025.101299
M3 - Article
C2 - 41461259
VL - 156
JO - The journal of nutrition
JF - The journal of nutrition
SN - 0022-3166
IS - 2
M1 - 101299
ER -